Appili Therapeutics Inc has seen a significant uptick in its stock price this week, reflecting market reactions to recent developments.
Appili Therapeutics Inc (APLI.TO) has experienced a notable performance this week, with a 50% increase in its stock price. The stock closed at C$0.01, marking a substantial change from previous levels. Investors may be curious about the factors contributing to this price movement and the overall state of the company in the healthcare sector.
Investor takeaway: While the recent price surge may attract attention, investors should consider the broader context of the company's operations and recent news that could impact future performance.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
+50.00%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
292.8%
Annualized
90-Day Vol
261.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.01 โ C$0.04 |
| 60 trading days | C$0.01 | C$0.00 โ C$0.06 |
| 90 trading days | C$0.01 | C$0.00 โ C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
C$0.01 closing price with a 50% increase this week.
Appili's stock has fluctuated within a 52-week range of C$0.01 to C$0.04, indicating volatility and potential investor caution.
Bull case
The company has made progress in its commercial-stage programs and secured significant funding, which could enhance its financial stability and growth potential.
Bear case
Despite the recent price increase, the stock is still down 40% year-to-date, and the termination of a key contract with the NIAID raises concerns about the company's future prospects.
Recent Price Action
This week, Appili Therapeutics Inc (APLI.TO) experienced a strong rally, with its stock price increasing by 50% to close at C$0.01. This notable rise comes amidst a backdrop of limited news, drawing attention from retail investors looking for opportunities in the healthcare sector.
Company News and Developments
Advertisement
Despite the significant price increase, there has been no major company news released this week that would directly explain the surge. However, headlines from recent months indicate ongoing challenges and opportunities for Appili. Notably, the company received a Notice of Termination from the National Institute of Allergy and Infectious Diseases (NIAID) regarding its VXV-01 program, which may have implications for its future funding and operational focus. Furthermore, Appili reported fiscal year 2026 financial results, highlighting advancements in its commercial-stage programs and substantial government funding.
Technical Picture
From a technical perspective, Appili's stock is currently trading at C$0.01, which is approximately 13.6% above its 50-day moving average of C$0.01 but 18.0% below its 200-day moving average of C$0.02. The stock has a 52-week range of C$0.01 to C$0.04, indicating that it is currently at the lower end of this range. The beta of -0.20 suggests that the stock has been less volatile than the broader market. Trading volume has been low, with the latest volume reported at 16,232 shares, significantly below the 20-day average volume of 93,555 shares.
Insider Activity
No recent insider activity has been reported for Appili Therapeutics Inc, which could indicate a lack of confidence from insiders or simply a period of stability in management decisions.
Price Action Summary
As of the last close, Appili Therapeutics Inc (APLI.TO) finished at C$0.01, reflecting a 50% increase over the week. While this price movement may attract speculative interest, investors should remain cautious and consider the broader implications of recent company developments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
